nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ACHE—kidney cancer	0.26	0.55	CbGaD
Mefloquine—BCHE—kidney cancer	0.153	0.323	CbGaD
Mefloquine—ABCB1—kidney cancer	0.0599	0.127	CbGaD
Mefloquine—CYP19A1—Paclitaxel—kidney cancer	0.0416	0.14	CbGbCtD
Mefloquine—ABCB1—Temsirolimus—kidney cancer	0.0257	0.086	CbGbCtD
Mefloquine—CYP2D6—Temsirolimus—kidney cancer	0.0242	0.081	CbGbCtD
Mefloquine—CYP3A4—Everolimus—kidney cancer	0.0228	0.0763	CbGbCtD
Mefloquine—CYP3A4—Temsirolimus—kidney cancer	0.0154	0.0515	CbGbCtD
Mefloquine—ABCB1—Pazopanib—kidney cancer	0.0135	0.0452	CbGbCtD
Mefloquine—CYP2D6—Pazopanib—kidney cancer	0.0127	0.0426	CbGbCtD
Mefloquine—ABCB1—Dactinomycin—kidney cancer	0.0123	0.0413	CbGbCtD
Mefloquine—HBA1—urine—kidney cancer	0.0107	0.324	CbGeAlD
Mefloquine—ABCB1—Gemcitabine—kidney cancer	0.00974	0.0327	CbGbCtD
Mefloquine—ABCB1—Erlotinib—kidney cancer	0.00962	0.0322	CbGbCtD
Mefloquine—CYP2D6—Erlotinib—kidney cancer	0.00906	0.0304	CbGbCtD
Mefloquine—ABCB1—Paclitaxel—kidney cancer	0.0088	0.0295	CbGbCtD
Mefloquine—CYP3A4—Pazopanib—kidney cancer	0.00807	0.0271	CbGbCtD
Mefloquine—ABCB1—Sorafenib—kidney cancer	0.00782	0.0262	CbGbCtD
Mefloquine—ABCB1—Vinblastine—kidney cancer	0.00772	0.0259	CbGbCtD
Mefloquine—ABCB1—Vincristine—kidney cancer	0.00759	0.0255	CbGbCtD
Mefloquine—CYP2D6—Sorafenib—kidney cancer	0.00737	0.0247	CbGbCtD
Mefloquine—CYP2D6—Vinblastine—kidney cancer	0.00727	0.0244	CbGbCtD
Mefloquine—ABCB1—Sunitinib—kidney cancer	0.00633	0.0212	CbGbCtD
Mefloquine—CYP3A4—Erlotinib—kidney cancer	0.00576	0.0193	CbGbCtD
Mefloquine—CYP3A4—Paclitaxel—kidney cancer	0.00527	0.0177	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—kidney cancer	0.00474	0.0159	CbGbCtD
Mefloquine—CYP3A4—Sorafenib—kidney cancer	0.00468	0.0157	CbGbCtD
Mefloquine—CYP3A4—Vinblastine—kidney cancer	0.00463	0.0155	CbGbCtD
Mefloquine—CYP3A4—Vincristine—kidney cancer	0.00455	0.0152	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—kidney cancer	0.00447	0.015	CbGbCtD
Mefloquine—CYP3A4—Sunitinib—kidney cancer	0.0038	0.0127	CbGbCtD
Mefloquine—CYP3A4—Doxorubicin—kidney cancer	0.00284	0.00953	CbGbCtD
Mefloquine—HBA1—renal system—kidney cancer	0.00262	0.0793	CbGeAlD
Mefloquine—HBA1—kidney—kidney cancer	0.00254	0.0766	CbGeAlD
Mefloquine—HBA2—renal system—kidney cancer	0.00241	0.0728	CbGeAlD
Mefloquine—HBA2—kidney—kidney cancer	0.00233	0.0704	CbGeAlD
Mefloquine—CYP3A4—urine—kidney cancer	0.00145	0.044	CbGeAlD
Mefloquine—CYP2D6—urine—kidney cancer	0.00143	0.0433	CbGeAlD
Mefloquine—ADORA2A—gonad—kidney cancer	0.00112	0.034	CbGeAlD
Mefloquine—ADORA1—renal system—kidney cancer	0.00108	0.0327	CbGeAlD
Mefloquine—ADORA1—kidney—kidney cancer	0.00105	0.0316	CbGeAlD
Mefloquine—ADORA1—cortex of kidney—kidney cancer	0.00102	0.0308	CbGeAlD
Mefloquine—ADORA1—cardiac atrium—kidney cancer	0.000969	0.0293	CbGeAlD
Mefloquine—CYP19A1—gonad—kidney cancer	0.000658	0.0199	CbGeAlD
Mefloquine—BCHE—nephron tubule—kidney cancer	0.000582	0.0176	CbGeAlD
Mefloquine—BCHE—cardiac atrium—kidney cancer	0.000474	0.0143	CbGeAlD
Mefloquine—CYP3A4—renal system—kidney cancer	0.000356	0.0108	CbGeAlD
Mefloquine—CYP2D6—renal system—kidney cancer	0.00035	0.0106	CbGeAlD
Mefloquine—CYP3A4—kidney—kidney cancer	0.000344	0.0104	CbGeAlD
Mefloquine—CYP2D6—kidney—kidney cancer	0.000339	0.0102	CbGeAlD
Mefloquine—ABCB1—nephron tubule—kidney cancer	0.000277	0.00838	CbGeAlD
Mefloquine—ABCB1—renal system—kidney cancer	0.000252	0.00762	CbGeAlD
Mefloquine—ABCB1—kidney—kidney cancer	0.000244	0.00736	CbGeAlD
Mefloquine—ABCB1—cortex of kidney—kidney cancer	0.000237	0.00717	CbGeAlD
Mefloquine—ABCB1—gonad—kidney cancer	0.000226	0.00683	CbGeAlD
Mefloquine—Vertigo—Paclitaxel—kidney cancer	8.73e-05	0.000689	CcSEcCtD
Mefloquine—Syncope—Paclitaxel—kidney cancer	8.71e-05	0.000688	CcSEcCtD
Mefloquine—Leukopenia—Paclitaxel—kidney cancer	8.69e-05	0.000687	CcSEcCtD
Mefloquine—Hypersensitivity—Sunitinib—kidney cancer	8.69e-05	0.000687	CcSEcCtD
Mefloquine—Decreased appetite—Vincristine—kidney cancer	8.67e-05	0.000685	CcSEcCtD
Mefloquine—Pruritus—Sorafenib—kidney cancer	8.67e-05	0.000685	CcSEcCtD
Mefloquine—Vomiting—Erlotinib—kidney cancer	8.67e-05	0.000685	CcSEcCtD
Mefloquine—Erythema multiforme—Capecitabine—kidney cancer	8.66e-05	0.000684	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	8.62e-05	0.000681	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Vincristine—kidney cancer	8.62e-05	0.000681	CcSEcCtD
Mefloquine—Fatigue—Vincristine—kidney cancer	8.6e-05	0.00068	CcSEcCtD
Mefloquine—Rash—Erlotinib—kidney cancer	8.59e-05	0.000679	CcSEcCtD
Mefloquine—Dermatitis—Erlotinib—kidney cancer	8.59e-05	0.000678	CcSEcCtD
Mefloquine—Palpitations—Paclitaxel—kidney cancer	8.58e-05	0.000678	CcSEcCtD
Mefloquine—Insomnia—Gemcitabine—kidney cancer	8.56e-05	0.000676	CcSEcCtD
Mefloquine—Eye disorder—Capecitabine—kidney cancer	8.56e-05	0.000676	CcSEcCtD
Mefloquine—Headache—Erlotinib—kidney cancer	8.54e-05	0.000675	CcSEcCtD
Mefloquine—Tinnitus—Capecitabine—kidney cancer	8.54e-05	0.000674	CcSEcCtD
Mefloquine—Loss of consciousness—Paclitaxel—kidney cancer	8.54e-05	0.000674	CcSEcCtD
Mefloquine—Paraesthesia—Gemcitabine—kidney cancer	8.5e-05	0.000672	CcSEcCtD
Mefloquine—Cardiac disorder—Capecitabine—kidney cancer	8.5e-05	0.000671	CcSEcCtD
Mefloquine—Flushing—Capecitabine—kidney cancer	8.5e-05	0.000671	CcSEcCtD
Mefloquine—Asthenia—Sunitinib—kidney cancer	8.46e-05	0.000669	CcSEcCtD
Mefloquine—Dyspnoea—Gemcitabine—kidney cancer	8.44e-05	0.000667	CcSEcCtD
Mefloquine—Nausea—Vinblastine—kidney cancer	8.42e-05	0.000665	CcSEcCtD
Mefloquine—Somnolence—Gemcitabine—kidney cancer	8.42e-05	0.000665	CcSEcCtD
Mefloquine—Convulsion—Paclitaxel—kidney cancer	8.41e-05	0.000665	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—kidney cancer	8.4e-05	0.000663	CcSEcCtD
Mefloquine—Nausea—Everolimus—kidney cancer	8.39e-05	0.000663	CcSEcCtD
Mefloquine—Diarrhoea—Sorafenib—kidney cancer	8.39e-05	0.000663	CcSEcCtD
Mefloquine—Hypertension—Paclitaxel—kidney cancer	8.38e-05	0.000662	CcSEcCtD
Mefloquine—Pruritus—Sunitinib—kidney cancer	8.35e-05	0.000659	CcSEcCtD
Mefloquine—Angiopathy—Capecitabine—kidney cancer	8.31e-05	0.000656	CcSEcCtD
Mefloquine—Chest pain—Paclitaxel—kidney cancer	8.27e-05	0.000653	CcSEcCtD
Mefloquine—Arthralgia—Paclitaxel—kidney cancer	8.27e-05	0.000653	CcSEcCtD
Mefloquine—Myalgia—Paclitaxel—kidney cancer	8.27e-05	0.000653	CcSEcCtD
Mefloquine—Mediastinal disorder—Capecitabine—kidney cancer	8.25e-05	0.000652	CcSEcCtD
Mefloquine—Anxiety—Paclitaxel—kidney cancer	8.24e-05	0.000651	CcSEcCtD
Mefloquine—Decreased appetite—Gemcitabine—kidney cancer	8.23e-05	0.00065	CcSEcCtD
Mefloquine—Hypersensitivity—Dactinomycin—kidney cancer	8.23e-05	0.00065	CcSEcCtD
Mefloquine—Chills—Capecitabine—kidney cancer	8.21e-05	0.000649	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.21e-05	0.000649	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.17e-05	0.000646	CcSEcCtD
Mefloquine—Discomfort—Paclitaxel—kidney cancer	8.17e-05	0.000645	CcSEcCtD
Mefloquine—Fatigue—Gemcitabine—kidney cancer	8.16e-05	0.000645	CcSEcCtD
Mefloquine—Gastrointestinal pain—Vincristine—kidney cancer	8.16e-05	0.000645	CcSEcCtD
Mefloquine—Dizziness—Sorafenib—kidney cancer	8.11e-05	0.000641	CcSEcCtD
Mefloquine—Nausea—Erlotinib—kidney cancer	8.1e-05	0.00064	CcSEcCtD
Mefloquine—Alopecia—Capecitabine—kidney cancer	8.09e-05	0.000639	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—kidney cancer	8.08e-05	0.000638	CcSEcCtD
Mefloquine—Diarrhoea—Sunitinib—kidney cancer	8.07e-05	0.000638	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—kidney cancer	8.02e-05	0.000634	CcSEcCtD
Mefloquine—Mental disorder—Capecitabine—kidney cancer	8.02e-05	0.000634	CcSEcCtD
Mefloquine—Asthenia—Dactinomycin—kidney cancer	8.01e-05	0.000633	CcSEcCtD
Mefloquine—Confusional state—Paclitaxel—kidney cancer	7.99e-05	0.000631	CcSEcCtD
Mefloquine—Malnutrition—Capecitabine—kidney cancer	7.97e-05	0.00063	CcSEcCtD
Mefloquine—Erythema—Capecitabine—kidney cancer	7.97e-05	0.00063	CcSEcCtD
Mefloquine—Anaphylactic shock—Paclitaxel—kidney cancer	7.93e-05	0.000626	CcSEcCtD
Mefloquine—Oedema—Paclitaxel—kidney cancer	7.93e-05	0.000626	CcSEcCtD
Mefloquine—Abdominal pain—Vincristine—kidney cancer	7.89e-05	0.000623	CcSEcCtD
Mefloquine—Body temperature increased—Vincristine—kidney cancer	7.89e-05	0.000623	CcSEcCtD
Mefloquine—Dizziness—Sunitinib—kidney cancer	7.8e-05	0.000616	CcSEcCtD
Mefloquine—Feeling abnormal—Gemcitabine—kidney cancer	7.8e-05	0.000616	CcSEcCtD
Mefloquine—Shock—Paclitaxel—kidney cancer	7.8e-05	0.000616	CcSEcCtD
Mefloquine—Vomiting—Sorafenib—kidney cancer	7.8e-05	0.000616	CcSEcCtD
Mefloquine—Nervous system disorder—Paclitaxel—kidney cancer	7.77e-05	0.000614	CcSEcCtD
Mefloquine—Thrombocytopenia—Paclitaxel—kidney cancer	7.76e-05	0.000613	CcSEcCtD
Mefloquine—Tachycardia—Paclitaxel—kidney cancer	7.74e-05	0.000611	CcSEcCtD
Mefloquine—Rash—Sorafenib—kidney cancer	7.73e-05	0.000611	CcSEcCtD
Mefloquine—Dermatitis—Sorafenib—kidney cancer	7.72e-05	0.00061	CcSEcCtD
Mefloquine—Skin disorder—Paclitaxel—kidney cancer	7.7e-05	0.000608	CcSEcCtD
Mefloquine—Headache—Sorafenib—kidney cancer	7.68e-05	0.000607	CcSEcCtD
Mefloquine—Muscle spasms—Capecitabine—kidney cancer	7.66e-05	0.000605	CcSEcCtD
Mefloquine—Hyperhidrosis—Paclitaxel—kidney cancer	7.66e-05	0.000605	CcSEcCtD
Mefloquine—Diarrhoea—Dactinomycin—kidney cancer	7.64e-05	0.000604	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—kidney cancer	7.52e-05	0.000594	CcSEcCtD
Mefloquine—Vision blurred—Capecitabine—kidney cancer	7.51e-05	0.000593	CcSEcCtD
Mefloquine—Vomiting—Sunitinib—kidney cancer	7.5e-05	0.000593	CcSEcCtD
Mefloquine—Body temperature increased—Gemcitabine—kidney cancer	7.48e-05	0.000591	CcSEcCtD
Mefloquine—Tremor—Capecitabine—kidney cancer	7.47e-05	0.00059	CcSEcCtD
Mefloquine—Rash—Sunitinib—kidney cancer	7.44e-05	0.000588	CcSEcCtD
Mefloquine—Dermatitis—Sunitinib—kidney cancer	7.43e-05	0.000587	CcSEcCtD
Mefloquine—Hypotension—Paclitaxel—kidney cancer	7.41e-05	0.000585	CcSEcCtD
Mefloquine—Ill-defined disorder—Capecitabine—kidney cancer	7.39e-05	0.000584	CcSEcCtD
Mefloquine—Headache—Sunitinib—kidney cancer	7.39e-05	0.000584	CcSEcCtD
Mefloquine—Hypersensitivity—Vincristine—kidney cancer	7.35e-05	0.000581	CcSEcCtD
Mefloquine—Nausea—Sorafenib—kidney cancer	7.28e-05	0.000575	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.22e-05	0.000571	CcSEcCtD
Mefloquine—Malaise—Capecitabine—kidney cancer	7.19e-05	0.000568	CcSEcCtD
Mefloquine—Insomnia—Paclitaxel—kidney cancer	7.17e-05	0.000566	CcSEcCtD
Mefloquine—Vertigo—Capecitabine—kidney cancer	7.16e-05	0.000566	CcSEcCtD
Mefloquine—Asthenia—Vincristine—kidney cancer	7.16e-05	0.000566	CcSEcCtD
Mefloquine—Syncope—Capecitabine—kidney cancer	7.15e-05	0.000565	CcSEcCtD
Mefloquine—Leukopenia—Capecitabine—kidney cancer	7.13e-05	0.000564	CcSEcCtD
Mefloquine—Paraesthesia—Paclitaxel—kidney cancer	7.12e-05	0.000562	CcSEcCtD
Mefloquine—Vomiting—Dactinomycin—kidney cancer	7.1e-05	0.000561	CcSEcCtD
Mefloquine—Dyspnoea—Paclitaxel—kidney cancer	7.07e-05	0.000558	CcSEcCtD
Mefloquine—Somnolence—Paclitaxel—kidney cancer	7.05e-05	0.000557	CcSEcCtD
Mefloquine—Palpitations—Capecitabine—kidney cancer	7.04e-05	0.000556	CcSEcCtD
Mefloquine—Rash—Dactinomycin—kidney cancer	7.04e-05	0.000556	CcSEcCtD
Mefloquine—Nausea—Sunitinib—kidney cancer	7.01e-05	0.000554	CcSEcCtD
Mefloquine—Loss of consciousness—Capecitabine—kidney cancer	7e-05	0.000553	CcSEcCtD
Mefloquine—Dyspepsia—Paclitaxel—kidney cancer	6.98e-05	0.000551	CcSEcCtD
Mefloquine—Decreased appetite—Paclitaxel—kidney cancer	6.89e-05	0.000544	CcSEcCtD
Mefloquine—Hypertension—Capecitabine—kidney cancer	6.88e-05	0.000544	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.84e-05	0.000541	CcSEcCtD
Mefloquine—Fatigue—Paclitaxel—kidney cancer	6.83e-05	0.00054	CcSEcCtD
Mefloquine—Diarrhoea—Vincristine—kidney cancer	6.83e-05	0.000539	CcSEcCtD
Mefloquine—Asthenia—Gemcitabine—kidney cancer	6.79e-05	0.000537	CcSEcCtD
Mefloquine—Arthralgia—Capecitabine—kidney cancer	6.78e-05	0.000536	CcSEcCtD
Mefloquine—Chest pain—Capecitabine—kidney cancer	6.78e-05	0.000536	CcSEcCtD
Mefloquine—Myalgia—Capecitabine—kidney cancer	6.78e-05	0.000536	CcSEcCtD
Mefloquine—Anxiety—Capecitabine—kidney cancer	6.76e-05	0.000534	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.74e-05	0.000532	CcSEcCtD
Mefloquine—Discomfort—Capecitabine—kidney cancer	6.7e-05	0.00053	CcSEcCtD
Mefloquine—Pruritus—Gemcitabine—kidney cancer	6.7e-05	0.000529	CcSEcCtD
Mefloquine—Nausea—Dactinomycin—kidney cancer	6.63e-05	0.000524	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—kidney cancer	6.61e-05	0.000522	CcSEcCtD
Mefloquine—Dizziness—Vincristine—kidney cancer	6.6e-05	0.000521	CcSEcCtD
Mefloquine—Confusional state—Capecitabine—kidney cancer	6.56e-05	0.000518	CcSEcCtD
Mefloquine—Feeling abnormal—Paclitaxel—kidney cancer	6.53e-05	0.000516	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	6.52e-05	0.000515	CcSEcCtD
Mefloquine—Oedema—Capecitabine—kidney cancer	6.5e-05	0.000514	CcSEcCtD
Mefloquine—Gastrointestinal pain—Paclitaxel—kidney cancer	6.48e-05	0.000512	CcSEcCtD
Mefloquine—Diarrhoea—Gemcitabine—kidney cancer	6.48e-05	0.000512	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—kidney cancer	6.46e-05	0.000511	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—kidney cancer	6.44e-05	0.000509	CcSEcCtD
Mefloquine—Shock—Capecitabine—kidney cancer	6.4e-05	0.000506	CcSEcCtD
Mefloquine—Nervous system disorder—Capecitabine—kidney cancer	6.38e-05	0.000504	CcSEcCtD
Mefloquine—Thrombocytopenia—Capecitabine—kidney cancer	6.37e-05	0.000503	CcSEcCtD
Mefloquine—Tachycardia—Capecitabine—kidney cancer	6.35e-05	0.000502	CcSEcCtD
Mefloquine—Vomiting—Vincristine—kidney cancer	6.34e-05	0.000501	CcSEcCtD
Mefloquine—Skin disorder—Capecitabine—kidney cancer	6.32e-05	0.000499	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—kidney cancer	6.3e-05	0.000498	CcSEcCtD
Mefloquine—Urticaria—Paclitaxel—kidney cancer	6.3e-05	0.000497	CcSEcCtD
Mefloquine—Rash—Vincristine—kidney cancer	6.29e-05	0.000497	CcSEcCtD
Mefloquine—Hyperhidrosis—Capecitabine—kidney cancer	6.29e-05	0.000497	CcSEcCtD
Mefloquine—Dermatitis—Vincristine—kidney cancer	6.29e-05	0.000497	CcSEcCtD
Mefloquine—Abdominal pain—Paclitaxel—kidney cancer	6.27e-05	0.000495	CcSEcCtD
Mefloquine—Body temperature increased—Paclitaxel—kidney cancer	6.27e-05	0.000495	CcSEcCtD
Mefloquine—Headache—Vincristine—kidney cancer	6.25e-05	0.000494	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—kidney cancer	6.22e-05	0.000491	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—kidney cancer	6.13e-05	0.000485	CcSEcCtD
Mefloquine—Hypotension—Capecitabine—kidney cancer	6.08e-05	0.00048	CcSEcCtD
Mefloquine—Vomiting—Gemcitabine—kidney cancer	6.02e-05	0.000476	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—kidney cancer	6.01e-05	0.000475	CcSEcCtD
Mefloquine—Rash—Gemcitabine—kidney cancer	5.97e-05	0.000472	CcSEcCtD
Mefloquine—Dermatitis—Gemcitabine—kidney cancer	5.96e-05	0.000471	CcSEcCtD
Mefloquine—Headache—Gemcitabine—kidney cancer	5.93e-05	0.000469	CcSEcCtD
Mefloquine—Nausea—Vincristine—kidney cancer	5.93e-05	0.000468	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.93e-05	0.000468	CcSEcCtD
Mefloquine—Insomnia—Capecitabine—kidney cancer	5.88e-05	0.000465	CcSEcCtD
Mefloquine—Paraesthesia—Capecitabine—kidney cancer	5.84e-05	0.000461	CcSEcCtD
Mefloquine—Hypersensitivity—Paclitaxel—kidney cancer	5.84e-05	0.000461	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—kidney cancer	5.8e-05	0.000458	CcSEcCtD
Mefloquine—Dyspnoea—Capecitabine—kidney cancer	5.8e-05	0.000458	CcSEcCtD
Mefloquine—Dyspepsia—Capecitabine—kidney cancer	5.73e-05	0.000452	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—kidney cancer	5.69e-05	0.000449	CcSEcCtD
Mefloquine—Asthenia—Paclitaxel—kidney cancer	5.69e-05	0.000449	CcSEcCtD
Mefloquine—Decreased appetite—Capecitabine—kidney cancer	5.65e-05	0.000447	CcSEcCtD
Mefloquine—Nausea—Gemcitabine—kidney cancer	5.62e-05	0.000444	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Capecitabine—kidney cancer	5.62e-05	0.000444	CcSEcCtD
Mefloquine—Fatigue—Capecitabine—kidney cancer	5.61e-05	0.000443	CcSEcCtD
Mefloquine—Pruritus—Paclitaxel—kidney cancer	5.61e-05	0.000443	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—kidney cancer	5.58e-05	0.000441	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—kidney cancer	5.51e-05	0.000436	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—kidney cancer	5.5e-05	0.000435	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—kidney cancer	5.48e-05	0.000433	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—kidney cancer	5.48e-05	0.000433	CcSEcCtD
Mefloquine—Diarrhoea—Paclitaxel—kidney cancer	5.42e-05	0.000428	CcSEcCtD
Mefloquine—Feeling abnormal—Capecitabine—kidney cancer	5.36e-05	0.000423	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—kidney cancer	5.35e-05	0.000423	CcSEcCtD
Mefloquine—Gastrointestinal pain—Capecitabine—kidney cancer	5.32e-05	0.00042	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—kidney cancer	5.32e-05	0.00042	CcSEcCtD
Mefloquine—Chills—Doxorubicin—kidney cancer	5.3e-05	0.000418	CcSEcCtD
Mefloquine—Dizziness—Paclitaxel—kidney cancer	5.24e-05	0.000414	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—kidney cancer	5.21e-05	0.000412	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—kidney cancer	5.17e-05	0.000408	CcSEcCtD
Mefloquine—Urticaria—Capecitabine—kidney cancer	5.17e-05	0.000408	CcSEcCtD
Mefloquine—Abdominal pain—Capecitabine—kidney cancer	5.14e-05	0.000406	CcSEcCtD
Mefloquine—Body temperature increased—Capecitabine—kidney cancer	5.14e-05	0.000406	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—kidney cancer	5.14e-05	0.000406	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—kidney cancer	5.14e-05	0.000406	CcSEcCtD
Mefloquine—Vomiting—Paclitaxel—kidney cancer	5.04e-05	0.000398	CcSEcCtD
Mefloquine—Rash—Paclitaxel—kidney cancer	5e-05	0.000395	CcSEcCtD
Mefloquine—Dermatitis—Paclitaxel—kidney cancer	4.99e-05	0.000394	CcSEcCtD
Mefloquine—Headache—Paclitaxel—kidney cancer	4.97e-05	0.000392	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—kidney cancer	4.94e-05	0.00039	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—kidney cancer	4.84e-05	0.000383	CcSEcCtD
Mefloquine—Hypersensitivity—Capecitabine—kidney cancer	4.79e-05	0.000379	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—kidney cancer	4.77e-05	0.000377	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—kidney cancer	4.72e-05	0.000373	CcSEcCtD
Mefloquine—Nausea—Paclitaxel—kidney cancer	4.71e-05	0.000372	CcSEcCtD
Mefloquine—Asthenia—Capecitabine—kidney cancer	4.67e-05	0.000369	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—kidney cancer	4.63e-05	0.000366	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—kidney cancer	4.62e-05	0.000365	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—kidney cancer	4.61e-05	0.000364	CcSEcCtD
Mefloquine—Pruritus—Capecitabine—kidney cancer	4.6e-05	0.000364	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—kidney cancer	4.6e-05	0.000363	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—kidney cancer	4.54e-05	0.000359	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—kidney cancer	4.52e-05	0.000357	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—kidney cancer	4.45e-05	0.000352	CcSEcCtD
Mefloquine—Diarrhoea—Capecitabine—kidney cancer	4.45e-05	0.000352	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—kidney cancer	4.44e-05	0.00035	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—kidney cancer	4.37e-05	0.000346	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—kidney cancer	4.37e-05	0.000346	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—kidney cancer	4.37e-05	0.000346	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—kidney cancer	4.36e-05	0.000344	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.34e-05	0.000343	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—kidney cancer	4.32e-05	0.000341	CcSEcCtD
Mefloquine—Dizziness—Capecitabine—kidney cancer	4.3e-05	0.00034	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—kidney cancer	4.23e-05	0.000334	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—kidney cancer	4.19e-05	0.000331	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—kidney cancer	4.19e-05	0.000331	CcSEcCtD
Mefloquine—Vomiting—Capecitabine—kidney cancer	4.14e-05	0.000327	CcSEcCtD
Mefloquine—Shock—Doxorubicin—kidney cancer	4.12e-05	0.000326	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—kidney cancer	4.11e-05	0.000325	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—kidney cancer	4.11e-05	0.000324	CcSEcCtD
Mefloquine—Rash—Capecitabine—kidney cancer	4.1e-05	0.000324	CcSEcCtD
Mefloquine—Dermatitis—Capecitabine—kidney cancer	4.1e-05	0.000324	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—kidney cancer	4.09e-05	0.000323	CcSEcCtD
Mefloquine—Headache—Capecitabine—kidney cancer	4.07e-05	0.000322	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—kidney cancer	4.07e-05	0.000322	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—kidney cancer	4.05e-05	0.00032	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—kidney cancer	3.92e-05	0.00031	CcSEcCtD
Mefloquine—Nausea—Capecitabine—kidney cancer	3.86e-05	0.000305	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.82e-05	0.000302	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—kidney cancer	3.79e-05	0.0003	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—kidney cancer	3.76e-05	0.000297	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—kidney cancer	3.74e-05	0.000295	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—kidney cancer	3.73e-05	0.000294	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—kidney cancer	3.69e-05	0.000292	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—kidney cancer	3.64e-05	0.000288	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.62e-05	0.000286	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—kidney cancer	3.61e-05	0.000286	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—kidney cancer	3.45e-05	0.000273	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—kidney cancer	3.43e-05	0.000271	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—kidney cancer	3.33e-05	0.000263	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—kidney cancer	3.31e-05	0.000262	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—kidney cancer	3.31e-05	0.000262	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—kidney cancer	3.09e-05	0.000244	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—kidney cancer	3.01e-05	0.000238	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—kidney cancer	2.97e-05	0.000234	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—kidney cancer	2.87e-05	0.000227	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—kidney cancer	2.77e-05	0.000219	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—kidney cancer	2.67e-05	0.000211	CcSEcCtD
Mefloquine—Rash—Doxorubicin—kidney cancer	2.64e-05	0.000209	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—kidney cancer	2.64e-05	0.000209	CcSEcCtD
Mefloquine—Headache—Doxorubicin—kidney cancer	2.63e-05	0.000208	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—kidney cancer	2.49e-05	0.000197	CcSEcCtD
Mefloquine—ABCB1—Metabolism—PPAT—kidney cancer	1.33e-05	0.000191	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GLIPR1—kidney cancer	1.33e-05	0.000191	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS1—kidney cancer	1.33e-05	0.000191	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.33e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FLT1—kidney cancer	1.32e-05	0.00019	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.32e-05	0.000189	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTT1—kidney cancer	1.31e-05	0.000187	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ACHE—kidney cancer	1.31e-05	0.000187	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PSMD7—kidney cancer	1.31e-05	0.000187	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF2—kidney cancer	1.3e-05	0.000186	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN2B—kidney cancer	1.29e-05	0.000186	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—MAPK1—kidney cancer	1.28e-05	0.000184	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.28e-05	0.000184	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ACHE—kidney cancer	1.27e-05	0.000182	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTT1—kidney cancer	1.27e-05	0.000182	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF1R—kidney cancer	1.26e-05	0.00018	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPAT—kidney cancer	1.26e-05	0.00018	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GLIPR1—kidney cancer	1.26e-05	0.00018	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—POMC—kidney cancer	1.25e-05	0.000179	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—POMC—kidney cancer	1.24e-05	0.000178	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—BCHE—kidney cancer	1.24e-05	0.000178	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—APRT—kidney cancer	1.24e-05	0.000178	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—FH—kidney cancer	1.24e-05	0.000178	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SCARB1—kidney cancer	1.24e-05	0.000177	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.24e-05	0.000177	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUNB—kidney cancer	1.23e-05	0.000176	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PAK1—kidney cancer	1.23e-05	0.000176	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS1—kidney cancer	1.22e-05	0.000176	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SLC5A5—kidney cancer	1.22e-05	0.000175	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.22e-05	0.000175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RAF1—kidney cancer	1.21e-05	0.000174	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PSMD7—kidney cancer	1.2e-05	0.000172	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SCARB1—kidney cancer	1.2e-05	0.000172	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL2—kidney cancer	1.2e-05	0.000171	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.19e-05	0.000171	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS1—kidney cancer	1.19e-05	0.00017	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ACY1—kidney cancer	1.18e-05	0.00017	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SLC2A1—kidney cancer	1.18e-05	0.000169	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—APRT—kidney cancer	1.17e-05	0.000167	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—FH—kidney cancer	1.17e-05	0.000167	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PSMD7—kidney cancer	1.17e-05	0.000167	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GPC3—kidney cancer	1.16e-05	0.000167	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.15e-05	0.000164	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—BCHE—kidney cancer	1.14e-05	0.000163	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.14e-05	0.000163	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—POMC—kidney cancer	1.13e-05	0.000163	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CA2—kidney cancer	1.13e-05	0.000162	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.13e-05	0.000162	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SLC5A5—kidney cancer	1.12e-05	0.000161	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—POMC—kidney cancer	1.11e-05	0.000159	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALAD—kidney cancer	1.1e-05	0.000158	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.1e-05	0.000157	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GPC3—kidney cancer	1.1e-05	0.000157	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SLC5A5—kidney cancer	1.09e-05	0.000156	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL2—kidney cancer	1.09e-05	0.000156	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SLC2A1—kidney cancer	1.09e-05	0.000156	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.08e-05	0.000155	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.08e-05	0.000154	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.08e-05	0.000154	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.07e-05	0.000153	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CA2—kidney cancer	1.07e-05	0.000153	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SLC2A1—kidney cancer	1.05e-05	0.000151	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.05e-05	0.000151	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.05e-05	0.000151	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.04e-05	0.000149	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALAD—kidney cancer	1.04e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HIF1A—kidney cancer	1.03e-05	0.000148	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TSC2—kidney cancer	1.03e-05	0.000148	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.02e-05	0.000147	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.02e-05	0.000146	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A3—kidney cancer	1.01e-05	0.000145	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PGK1—kidney cancer	1.01e-05	0.000145	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PDHB—kidney cancer	1.01e-05	0.000144	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF2—kidney cancer	1e-05	0.000144	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—POMC—kidney cancer	1e-05	0.000144	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1e-05	0.000143	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN2B—kidney cancer	1e-05	0.000143	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	9.92e-06	0.000142	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—LDHB—kidney cancer	9.9e-06	0.000142	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KDR—kidney cancer	9.9e-06	0.000142	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTP1—kidney cancer	9.85e-06	0.000141	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1R—kidney cancer	9.71e-06	0.000139	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PGK1—kidney cancer	9.51e-06	0.000136	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A3—kidney cancer	9.51e-06	0.000136	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CCBL1—kidney cancer	9.47e-06	0.000136	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	9.41e-06	0.000135	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RAF1—kidney cancer	9.35e-06	0.000134	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—LDHB—kidney cancer	9.33e-06	0.000134	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ABCB1—kidney cancer	9.33e-06	0.000134	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL2—kidney cancer	9.23e-06	0.000132	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.19e-06	0.000132	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—APC—kidney cancer	9.12e-06	0.000131	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KIT—kidney cancer	9.12e-06	0.000131	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTP1—kidney cancer	9.06e-06	0.00013	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTM1—kidney cancer	9.06e-06	0.00013	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.92e-06	0.000128	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	8.9e-06	0.000128	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CTNNB1—kidney cancer	8.86e-06	0.000127	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTP1—kidney cancer	8.79e-06	0.000126	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—MAPK3—kidney cancer	8.73e-06	0.000125	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—POMC—kidney cancer	8.68e-06	0.000124	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	8.66e-06	0.000124	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CA9—kidney cancer	8.58e-06	0.000123	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP1A1—kidney cancer	8.58e-06	0.000123	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ABCB1—kidney cancer	8.57e-06	0.000123	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—BRAF—kidney cancer	8.57e-06	0.000123	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	8.47e-06	0.000121	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL2—kidney cancer	8.39e-06	0.00012	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTM1—kidney cancer	8.32e-06	0.000119	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ABCB1—kidney cancer	8.32e-06	0.000119	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—MAPK1—kidney cancer	8.31e-06	0.000119	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPAT—kidney cancer	8.21e-06	0.000118	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.21e-06	0.000118	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CA9—kidney cancer	8.09e-06	0.000116	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTM1—kidney cancer	8.08e-06	0.000116	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	8e-06	0.000115	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HIF1A—kidney cancer	7.99e-06	0.000115	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TSC2—kidney cancer	7.97e-06	0.000114	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CA—kidney cancer	7.94e-06	0.000114	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CTNNB1—kidney cancer	7.91e-06	0.000113	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP1A1—kidney cancer	7.89e-06	0.000113	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—kidney cancer	7.85e-06	0.000113	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP1A1—kidney cancer	7.66e-06	0.00011	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KDR—kidney cancer	7.64e-06	0.00011	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FH—kidney cancer	7.63e-06	0.000109	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—APRT—kidney cancer	7.63e-06	0.000109	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	7.35e-06	0.000105	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CRABP1—kidney cancer	7.3e-06	0.000105	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—kidney cancer	7.21e-06	0.000103	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPC3—kidney cancer	7.17e-06	0.000103	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RAF1—kidney cancer	7.16e-06	0.000103	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RELA—kidney cancer	7.12e-06	0.000102	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	7.11e-06	0.000102	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—kidney cancer	7.08e-06	0.000101	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.05e-06	0.000101	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—APC—kidney cancer	7.04e-06	0.000101	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—kidney cancer	7.04e-06	0.000101	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MTOR—kidney cancer	6.99e-06	0.0001	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA2—kidney cancer	6.98e-06	0.0001	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CRABP1—kidney cancer	6.88e-06	9.86e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALAD—kidney cancer	6.8e-06	9.75e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ITPR2—kidney cancer	6.79e-06	9.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK3—kidney cancer	6.74e-06	9.67e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—POMC—kidney cancer	6.7e-06	9.61e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.64e-06	9.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BRAF—kidney cancer	6.62e-06	9.49e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1B—kidney cancer	6.56e-06	9.4e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.49e-06	9.3e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.48e-06	9.29e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—kidney cancer	6.42e-06	9.2e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK1—kidney cancer	6.41e-06	9.2e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—POMC—kidney cancer	6.4e-06	9.18e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ITPR2—kidney cancer	6.39e-06	9.17e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.29e-06	9.02e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—kidney cancer	6.25e-06	8.97e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—kidney cancer	6.24e-06	8.95e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PGK1—kidney cancer	6.22e-06	8.92e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.22e-06	8.92e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—kidney cancer	6.19e-06	8.88e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ACHE—kidney cancer	6.19e-06	8.87e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—kidney cancer	6.19e-06	8.87e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—kidney cancer	6.13e-06	8.79e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—LDHB—kidney cancer	6.1e-06	8.75e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—kidney cancer	6.06e-06	8.69e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—kidney cancer	6.04e-06	8.65e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—POMC—kidney cancer	5.88e-06	8.43e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SCARB1—kidney cancer	5.86e-06	8.4e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—kidney cancer	5.83e-06	8.36e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ACHE—kidney cancer	5.83e-06	8.36e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS1—kidney cancer	5.8e-06	8.31e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—POMC—kidney cancer	5.71e-06	8.19e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PSMD7—kidney cancer	5.69e-06	8.15e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.57e-06	7.98e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RAF1—kidney cancer	5.52e-06	7.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SCARB1—kidney cancer	5.52e-06	7.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RELA—kidney cancer	5.5e-06	7.89e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—kidney cancer	5.47e-06	7.84e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS1—kidney cancer	5.46e-06	7.83e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—kidney cancer	5.45e-06	7.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MTOR—kidney cancer	5.39e-06	7.73e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—BCHE—kidney cancer	5.39e-06	7.73e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PSMD7—kidney cancer	5.36e-06	7.68e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A5—kidney cancer	5.33e-06	7.63e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA9—kidney cancer	5.29e-06	7.58e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK3—kidney cancer	5.16e-06	7.39e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC2A1—kidney cancer	5.14e-06	7.37e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—kidney cancer	5.11e-06	7.32e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—BCHE—kidney cancer	5.08e-06	7.28e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—kidney cancer	5.06e-06	7.26e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.02e-06	7.19e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—kidney cancer	5.02e-06	7.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—kidney cancer	4.95e-06	7.1e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK1—kidney cancer	4.91e-06	7.04e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.9e-06	7.03e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.85e-06	6.95e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—kidney cancer	4.83e-06	6.92e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—kidney cancer	4.82e-06	6.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—kidney cancer	4.78e-06	6.86e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—kidney cancer	4.69e-06	6.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—kidney cancer	4.66e-06	6.68e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—kidney cancer	4.64e-06	6.65e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—kidney cancer	4.55e-06	6.53e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CRABP1—kidney cancer	4.5e-06	6.45e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—kidney cancer	4.45e-06	6.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—kidney cancer	4.29e-06	6.15e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—kidney cancer	4.26e-06	6.11e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—kidney cancer	4.21e-06	6.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ITPR2—kidney cancer	4.18e-06	5.99e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—kidney cancer	4.12e-06	5.91e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—kidney cancer	4.09e-06	5.87e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—kidney cancer	4.04e-06	5.79e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK3—kidney cancer	3.98e-06	5.71e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—kidney cancer	3.97e-06	5.69e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—kidney cancer	3.94e-06	5.65e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—kidney cancer	3.87e-06	5.55e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—kidney cancer	3.83e-06	5.49e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ACHE—kidney cancer	3.81e-06	5.47e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—kidney cancer	3.81e-06	5.47e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK1—kidney cancer	3.79e-06	5.43e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1A1—kidney cancer	3.74e-06	5.36e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—kidney cancer	3.71e-06	5.33e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SCARB1—kidney cancer	3.61e-06	5.17e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—kidney cancer	3.58e-06	5.13e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS1—kidney cancer	3.57e-06	5.12e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.52e-06	5.05e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PSMD7—kidney cancer	3.5e-06	5.02e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—BCHE—kidney cancer	3.32e-06	4.76e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—kidney cancer	3.29e-06	4.71e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.28e-06	4.7e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—kidney cancer	3.18e-06	4.56e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.17e-06	4.54e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—kidney cancer	3.14e-06	4.5e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—kidney cancer	2.89e-06	4.14e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—kidney cancer	2.8e-06	4.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—POMC—kidney cancer	2.79e-06	3.99e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—kidney cancer	2.64e-06	3.79e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—POMC—kidney cancer	2.63e-06	3.76e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—kidney cancer	2.5e-06	3.59e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—kidney cancer	2.43e-06	3.48e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.3e-06	3.3e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—kidney cancer	2.22e-06	3.19e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—kidney cancer	2.09e-06	3e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—kidney cancer	1.94e-06	2.78e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—kidney cancer	1.83e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—POMC—kidney cancer	1.72e-06	2.46e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—kidney cancer	1.37e-06	1.96e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—kidney cancer	1.37e-06	1.96e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.29e-06	1.85e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—kidney cancer	1.19e-06	1.71e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.42e-07	1.21e-05	CbGpPWpGaD
